The incretin effect: An interview with Dr. Daniel Drucker
University of Toronto Medical Journal · 11.05.2026 · 103 (2)
DOI: 10.33137/utmj.v103i2.47411 ↗Kurz gefasst
Fachartikel in der Zeitschrift University of Toronto Medical Journal, online erschienen am 11.05.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dr. Daniel Drucker is a clinician scientist at the Lunenfeld-Tanenbaum Research Institute, University of Toronto. His laboratory studies the translational biology of glucagon-like peptides (GLPs). His work in this space helped define the biological actions of GLP-1 and laid the scientific foundation for the development of GLP-1-based therapies globally, which are now widely used in the treatment of diabetes and obesity.
Zitieren
APA
(2026). The incretin effect: An interview with Dr. Daniel Drucker. University of Toronto Medical Journal, 103(2). https://doi.org/10.33137/utmj.v103i2.47411
Vancouver
The incretin effect: An interview with Dr. Daniel Drucker. University of Toronto Medical Journal. 2026;103(2). doi:10.33137/utmj.v103i2.47411
BibTeX
@article{euvimed2026,
title = {The incretin effect: An interview with Dr. Daniel Drucker},
journal = {University of Toronto Medical Journal},
year = {2026},
volume = {103},
number = {2},
doi = {10.33137/utmj.v103i2.47411}
}
EUVIMED